Prostanoid compounds and pharmaceutical formulations
US4438111A · kind A · utility
3Cited by
7References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 17, 1982 |
| Grant date | Mar 20, 1984 |
| Priority date | — |
| Expiry date | Sep 17, 2002 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D333/28
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Prostanoids are described of the formulae ##STR1## (and the salts thereof) in which: X is cis or trans--CH.dbd.CH-- or CH.sub.2 CH.sub.2 --; PA1 R.sup.1 is C.sub.1-7 alkyl terminated by --COOR.sup.10 where R.sup.10 is H, C.sub.1-6 alkyl or aralkyl; PA1 Y is a saturtaed heterocyclic amino group; and PA1 R.sup.4 is thienylalkyl or furanylalkyl in which the ring may be substituted. These compounds inhibit blood platelet aggregation and have bronchodilatory action, and may be formulated for use as anti-asthmatics and antithrombotic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.